Sun Pharmaceutical Industries said in a regulatory filing that one of its wholly-owned subsidiaries has entered into an agreement with Nostrum Laboratories Inc for the divestment of the Bryan (Ohio) unit in the US. 

As a part of the agreement, the undisclosed Sun Pharma subsidiary has divested the unit as a going concern along with the employees and related products to Nostrum.

In September, the company had said that it plans to sell a manufacturing facility in Ireland that was owned by Ranbaxy.

Sun completed the USD 4 billion acquisition of Ranbaxy in March, almost a year after announcing the deal.

Sun Pharma shares today ended at Rs 768.60 apiece on the BSE, up 1.39 percent from previous close.

Latest News  from Business News Desk